A team at Massachusetts General Hospital conducted research to evaluate the expression levels of the extracellular matrix protein tubulointerstitial nephritis antigen-like 1 (TINAGL1) in the human ovary.

Epithelial ovarian cancer (EOC) is the most predominant histologic type of ovarian cancer, with about 55% of patients at an advanced stage when diagnosed; overall survival remains poor.

Scientists at Massachusetts General Hospital have linked the risk of heart failure during pregnancy and senescence proteins produced by placental aging, which could clarify how peripartum cardiomyopathy (PPCM) is triggered and opens the door to the development of cardiac function therapies in late pregnancy.

Aska Pharmaceutical Co. Ltd., a subsidiary of Aska Pharmaceutical Holdings Co. Ltd., and Red Arrow Therapeutics Inc. have signed a joint research agreement to develop a new treatment for preeclampsia using advanced nanotechnology.

Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.

About 75% of patients with ovarian cancer are diagnosed with advanced disease. It is hence of high importance to explore reliable biomarkers and their mechanisms during pathology. Growing evidence exists regarding long noncoding RNAs (lncRNAs) as regulatory factors in several cellular processes.

Listening to conversations between a mother and her unborn child on the cellular level could inform how the pregnancy is going and prevent complications. Three scientific groups from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), in collaboration with Wayne State University and Michigan State University, have used single-cell RNA sequencing techniques to decipher these words, identify the cellular language of these interactions in the placenta and establish a cellular atlas.

Polycystic ovary syndrome (PCOS) is a form of anovulatory infertility characterized by hyperandrogenemia, irregular menses and polycystic ovarian morphology. Apart from experiencing reproductive-related symptoms, women with PCOS face an increased risk of obesity, insulin resistance and type 2 diabetes.

Celmatix Inc. and Aché Laboratórios Farmacéuticos SA will study the role of melatonin receptors and their agonists in polycystic ovary syndrome (PCOS). The two companies announced a collaboration, with a separate license and development agreement upon conclusion of the research.

A new study has shown that a uterine bacterium is one cause of endometriosis and that preventing the infection could prevent development of the pathology, in which tissue similar to the lining of the uterus grows in the abdominal cavity.